Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125276311 | 12527631 | 1 | I | 20160620 | 20160705 | 20160705 | EXP | US-IPCA LABORATORIES LIMITED-IPC201606-000548 | IPCA | MACCA A. THE TREATMENT OF MIGRAINE HEADACHE IN THE PRESENCE OF SELECTIVE SEROTONIN REUPTAKE INHIBITOR USE: PHARMACOKINETIC CONSIDERATIONS. J NEUROSCI NURS 2015 AUG;47(4):235-8. | 34.00 | YR | F | Y | 0.00000 | 20160705 | OT | COUNTRY NOT SPECIFIED | US |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125276311 | 12527631 | 1 | PS | Ondansetron | ONDANSETRON | 1 | Intravenous (not otherwise specified) | Y | 203761 | 32 | MG | ||||||||
| 125276311 | 12527631 | 2 | SS | Ondansetron | ONDANSETRON | 1 | Y | 203761 | |||||||||||
| 125276311 | 12527631 | 3 | SS | ALMOTRIPTAN. | ALMOTRIPTAN | 1 | Y | 0 | 12.5 | MG | |||||||||
| 125276311 | 12527631 | 4 | SS | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Y | 0 | 40 | MG | |||||||||
| 125276311 | 12527631 | 5 | SS | FLUOXETINE | FLUOXETINE HYDROCHLORIDE | 1 | Y | 0 | |||||||||||
| 125276311 | 12527631 | 6 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | 2 | MG | BID | |||||||||
| 125276311 | 12527631 | 7 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | 2 | MG | ||||||||||
| 125276311 | 12527631 | 8 | C | LORAZEPAM. | LORAZEPAM | 1 | 0 | ||||||||||||
| 125276311 | 12527631 | 9 | C | IBUPROFEN. | IBUPROFEN | 1 | 0 | ||||||||||||
| 125276311 | 12527631 | 10 | C | ACETAMINOPHEN. | ACETAMINOPHEN | 1 | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125276311 | 12527631 | 1 | Nausea |
| 125276311 | 12527631 | 2 | Anxiety |
| 125276311 | 12527631 | 3 | Headache |
| 125276311 | 12527631 | 4 | Anxiety |
| 125276311 | 12527631 | 5 | Sleep disorder |
| 125276311 | 12527631 | 6 | Anxiety |
| 125276311 | 12527631 | 7 | Sleep disorder |
| 125276311 | 12527631 | 8 | Nausea |
| 125276311 | 12527631 | 9 | Myalgia |
| 125276311 | 12527631 | 10 | Myalgia |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125276311 | 12527631 | HO |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125276311 | 12527631 | Drug interaction | |
| 125276311 | 12527631 | Serotonin syndrome |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| no results found |